Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.78 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.78 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 0.54 |
| ▸ | TNF | P01375 | 1/20 | 0.53 |
| ▸ | IL1B | P01584 | 1/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.53 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.53 |
| ▸ | STAT3 | P40763 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29549536 | 1.00 | CRBN (0.78) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL14085574 | 0.88 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL19481530 | 0.86 | DDB1 (0.83) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL17839798 | 0.85 | DDB1 (0.81) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL24746775 | 0.85 | DDB1 (0.81) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL29360230 | 0.85 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL14085581 | 0.85 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL14085580 | 0.84 | DDB1 (0.75) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL18379320 | 0.84 | CRBN (0.83) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL17884453 | 0.84 | CRBN (0.83) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177466-A1 | DEGRADERS OF KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 (KEAP1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220177466-A1 | DEGRADERS OF KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 (KEAP1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| EP-3953337-A1 | DEGRADERS OF KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 (KEAP1) | Dana-Farber Cancer Institute, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-11066391-B1 | Atorvastatin derived HMG-CoA reductase degradation inducing compound | UPPTHERA (KR) | 2021-07-20 | — | — | US | disclosed |
| US-11066391-B1 | Atorvastatin derived HMG-CoA reductase degradation inducing compound | UPPTHERA (KR) | 2021-07-20 | — | — | US | disclosed |
| WO-2020210229-A1 | DEGRADERS OF KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 (KEAP1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177466-A1 | DEGRADERS OF KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 (KEAP1) | KEAP1, NFE2L2, GSTK1 | CRBN 250/4885DDB1 106/4885IKZF3 595/4885 |
| US-11066391-B1 | Atorvastatin derived HMG-CoA reductase degradation inducing compound | HMGCR, LDLR, HMGB2 | CRBN 1054/4885DDB1 441/4885IKZF3 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.